April 2022 Global Biomedical Investment and Financing Monthly Report
I. Overview of Global Biomedical Financing in April 2022
According to incomplete statistics from the Artery Orange Industry Think Tank, in April 2022, there were 82 financing incidents in the global biomedical field (excluding IPOs, private placements, etc.), and the total amount of disclosed financing was about US$2.727 billion (about 17.73 billion yuan), down about 9% from the previous month.
Specifically, the domestic biomedical field has generated a total of 39 financing projects, with a total financing of about US$568 million, down about 47% from the previous month; a total of 43 projects in the overseas biomedical field have been completed, with a total of nearly US$2.16 billion, a total increase of about 13% from the previous month.
1) Comparison of global biomedical financing events from November 2021 to April 2022
From the aspects of transaction amount, number of financing events and focus on emerging areas, compared with the investment and financing situation of the global biomedical market in March 2022, the amount of global biomedical investment and financing in April 2022 showed a downward trend.
There were 10 over $100 million financing incidents this month, double the previous month, and the over-100 million dollar financing events are mainly concentrated in the biopharmaceutical segment. Among them, Tessera Therapeutics, a developer of gene therapy and gene editing technology, won the top spot with $300 million in round C financing.
2) Comparison of global biomedical financing events in March and April 2022
In April 2022, there were 68 public rounds of financing events in the global biomedical field and 14 financing events in the undisclosed rounds. The financing rounds are mainly concentrated in the A round, B round, seed round/angel round, accounting for nearly 72% of the total number of financing events.
Compared with March, except for the undisclosed rounds, other rounds are decreasing, indicating that investment institutions are more focused and cautious in betting, and the number of investments has tightened. At the same time, there was only one Series D and later incident this month, and Alzheon, a developer of neurological treatment drugs from overseas, completed an oversubscripted $50 million Series D financing. The proceeds from this round of funding will be used to accelerate the development of the drug candidate ALZ-801, an oral agent in three-phase development that is a treatment that alters AD disease and blocks the formation of neurotoxic soluble amyloid oligomers that cause cognitive decline in Alzheimer's patients.
(Note: Combine the angel round, seed round, seed VC, etc. into the angel round, all the rounds with A into the A round, all the rounds with B into the B round, all the rounds with C into the C round, and the rounds below the C above the IPO into the D round and above.) ）
3) Ranking of financing events in the global biomedical segment in April 2022
In terms of financing in the biomedical segment, this month chemical pharmaceutical surpassed the R&D manufacturing outsourcing segment, ranking second. There were 46 funding incidents in the biopharmaceutical sector, with a total disclosed transaction value of nearly $1.903 billion, down 5% sequentially.
It is worth mentioning that Kelonia Therapeutics, the developer of genetic drugs, completed a $50 million Series A financing. Kelonia Therapeutic is pioneering new gene drugs with its next-generation gene delivery platform, which initially focused on developing translational therapies for solid tumors and blood system cancers, is building a gene drug pipeline for a variety of diseases, with the goal of delivering gene drugs to every patient who needs them.
2. Global biomedical field - financing event in April 2022
This article only shows part of the monthly report, please click on the topic: https://vbdata.cn/specialDetail/3f87086595f257a2658209ce927f54f9 to view all the content
The data comes from the Arterial Orange Industry Think Tank.